Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:51 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)
NCT00073372 · Centocor, Inc. · PHASE3 · terminated · last registry update 2011-05-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Based on the data and observed benefit-risk profile, the trial's independent oversight committee recommended that enrollment not resume.” | – | Registry record, Centocor, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ITGB3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2012-05-15Phase 3 first posted: Prince Sultan Cardiac Center, Adult Cardiology Department., Aspirin + Tirofiban (NCT01598337)
- 2012-03-22Also stopped (terminated): Bart Neyns, Cetuximab + Cilengitide EMD 121974 (NCT01044225)
- 2011-09-14Phase 3 first posted: Italian Society of Invasive Cardiology, a drug against ITGB3 (NCT01433627)
- 2011-04-15Phase 3 first posted: Università degli Studi di Ferrara, Prasugrel + Tirofiban (NCT01336348)
- 2010-11-22Phase 3 first posted: Medicure, Tirofiban (Aggrastat) + Placebo (NCT01245725)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision